At AAPS with CritiTech Particle Engineering Solutions

At a recent American Association of Pharmaceutical Scientists (AAPS) convention, BioPharm International sat down with Matthew McClorey, President of CritiTech Particle Engineering Solutions.

Learn more about:

• What makes CritiTech unique in the CDMO market.
• What you can expect from working with CritiTech.
• The company’s ability to formulate direct-to-site treatments from previously systemically delivered drugs with the patented Purcision platform.